Phase II Trial of Autologous Peripheral Blood Hematopoietic Cell Transplantation (PBHCT) Followed by Dendritic Cell p53 Vaccination and Adoptive T Cell Transfer in Patients With Limited Stage Small Cell Lung Cancer.

Trial Profile

Phase II Trial of Autologous Peripheral Blood Hematopoietic Cell Transplantation (PBHCT) Followed by Dendritic Cell p53 Vaccination and Adoptive T Cell Transfer in Patients With Limited Stage Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs INGN 225 (Primary) ; Cyclophosphamide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2012 Actual initiation date changed from 1 Apr 2007 to 1 May 2007 and actual patient number changed from 4 to 2 as reported by ClinicalTrials.gov.
    • 20 Jun 2012 Actual initiation date changed from 1 Apr 2007 to 1 May 2007 and actual patient number changed from 4 to 2 as reported by ClinicalTrials.gov.
    • 04 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top